Welcome to Markets Desk, your midday read on what's moving money and markets.
Tesla posted a genuine earnings beat this week, topping both revenue and profit expectations for the third quarter, but shares still pulled back as investors looked past the headline numbers. One five-star analyst is pushing back on that reaction, arguing sellers are moving too fast on a name with meaningful long-term runway still ahead.
Shifting to healthcare, Johnson and Johnson released early Phase one clinical data for JNJ-six one four three, an investigational oral treatment targeting advanced prostate cancer. The results showed significant anti-tumor activity in patients who had already exhausted multiple prior treatment lines, a meaningful signal at this stage that will draw close attention as the program advances toward later trials.
And on the consumer side, the student loan pressure story is getting harder to ignore. Borrowers are actively cutting groceries, delaying home purchases, and trimming discretionary spending as monthly payments surge. The macro read here matters — when millions of households tighten simultaneously, that demand destruction shows up in retail and housing data before it shows up in headlines.
That's the tape. Markets Desk, signing off the floor.
